
	Where results make sense

Topic: Dyslipidemia

Related Topics

Hyperlipidemia

Obesity

Maxine Carr

Life imprisonment

Contempt of court

Jeffrey Archer

Perverting the course of justice

Neil Hamilton

Perjury

Grimsby

Obstruction of justice

In the News (Fri 18 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, ...
		Dyslipidemia and insulin resistance, known metabolic associations with lipodystrophy, were also associated with increased risk of myocardial infarction in these patients.
		Although longitudinal data for the consequences of dyslipidemia are lacking in the pediatric population, the hypothesized consequence would be the development of premature atherosclerotic disease.
		HIV-infected children with dyslipidemia would likely be at risk for accelerated atherosclerotic disease because of their elevations in total serum cholesterol, LDL, and triglycerides, plus, as is discussed elsewhere, their potential comorbid conditions (including increased waist-to-hip ratios, insulin resistance, and mitochondrial toxicity).
	www.natap.org /2004/HIV/082004_03.htm (6465 words)

	Diabetes In Control Dot Com. The FREE weekly newsletter for Medical Professionals in Diabetes care. (Site not responding. Last check: 2007-11-03)
		Diabetic dyslipidemia appears to be a very important component of the accelerated atherogenesis that occurs in patients with diabetes.
		dyslipidemia appears to be a central characteristic component of the insulin resistance syndrome.
		Dyslipidemia and hypertension are integral parts of the type 2 diabetic syndrome and are closely linked to the major cause of morbidity and mortality, ASCVD, in patients with this disorder.
	www.diabetesincontrol.com /cholesterol.htm (777 words)

	HYPERLIPIDEMIA AMONG SAUDI DIABETIC PATIENTS - PATTERN AND CLINIC CHARACTERISTICS: 15(3)
		Dyslipidemia, which has a frequent occurrence among diabetics, has been shown to be the main contributor to the increased incidence of coronary events and deaths among diabetic subjects.
		The Association of Atherosclerosis, Dyslipidemia and Diabetes was recognized as early as 1927, when Joslin1 suggested that the cause of premature development of atherosclerosis among diabetic subjects was related to excess fat.
		The reported prevalence of diabetic dyslipidemia has varied from 25% to 60%.10 This wide variation can be attributed to the studied population and the degree of glycemic control and to the variation of the definition of the "cut-off" for hypercholesterolemia and hypertri-glyceridemia.
	www.kfshrc.edu.sa /annals/153/94135.html (1831 words)

	Dyslipidemia
		The major goal in treatment of patients with dyslipidemia is to decrease the short- and long-term incidence of cardiovascular events, including myocardial infarction, unstable angina, stroke, and death.
		Dyslipidemia exists when any aspect of the lipid profile is abnormal.
		What is especially remarkable about these numbers is that this study required active treatment of dyslipidemia as an inclusion criterion, so one cannot blame the poor results on simple ignorance of the problem.
	www.treatment-options.com /article.cfm?PubID=CM03-4-2-05&Type=Article&KeyWords= (4800 words)

	Dyslipidemia Type 2 Diabetes Dyslipidemia Type 2 Diabetes Overview Dyslipidemia Type 2 Diabetes Description (Site not responding. Last check: 2007-11-03)
		Dyslipidemia is common in persons with type 2 diabetes—which accounts for 90% to 95% of all cases of diabetes
		Practitioners are in a position to reduce the incidence of CHD and other vascular disorders in their patients by appropriate treatment of diabetes and diabetic dyslipidemia, which is modifiable.
		Diabetic dyslipidemia is characterized by elevated TG, decreased HDL-C, and a predominance of atherogenic small, dense LDL particles.
	www.dyslipidemia.org /dyslipidemia-type-2-diabetes.html (645 words)

	Section 9 Chapter II Diagnosis and Treatment of Dyslipidemia (Site not responding. Last check: 2007-11-03)
		The dyslipidemia of the metabolic syndrome can be diagnosed by demonstrating mild to moderate increases in plasma triglyceride and apo B levels, decreased levels of HDL cholesterol, and normal levels of LDL.
		Polygenic hypercholesterolemia is a term used to refer to the occurrence of mild elevations in LDL cholesterol in the apparent absence of a familial form of dyslipidemia or of dyslip idemia of secondary cause.
		The predominant dyslipidemia that is seen in patients with AIDS is similar to the dyslipidemia that occurs in patients with the metabolic syndrome; mild hypertriglyceridemia is common, and low HDL cholesterol is seen in some patients.
	www.acpmedicine.com /sample/ch0902s.htm (16090 words)

	People With High Blood Pressure Often Have High Cholesterol, Too - Swedish Medical Center, Seattle, Washington
		Dyslipidemia (cholesterol problems or high triglycerides), another major risk factor for heart attack and stroke, is reported in 50% to 80% of people with high blood pressure.
		And the likelihood of having dyslipidemia in addition to high blood pressure varied significantly between fls and whites, and between men and women.
		The fact that dyslipidemia treatment was more common in certain groups (whites and men) suggests that there is a disturbing problem of differential treatment for cardiovascular disease.
	www.swedish.org /19267.cfm (813 words)

	Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
		Dyslipidemia and insulin resistance are two key components of the metabolic syndrome, which is often exhibited in patients with type 2 diabetes.
		In each of the four trials, patients with poorly controlled type 2 diabetes were randomized to receive monotherapy consisting of ACTOS, metformin or a sulfonylurea (gliclazide), or a combination of ACTOS with these two agents.
		A second study presented at the ADA Scientific Sessions demonstrated that, in people with type 2 diabetes and dyslipidemia, ACTOS had a robust effect on both lipid and glucose levels, regardless of whether the patient was receiving stable lipid-lowering therapy.
	www.eurekalert.org /pub_releases/2004-06/k-ssa060604.php (881 words)

	The American Journal of Managed Care: Prevalence of Comorbid Hypertension and Dyslipidemia and Associated ...
		Objectives: To estimate the prevalence of concurrent hypertension and dyslipidemia among a general veteran population and separately among patients with diabetes mellitus, and to compare the prevalence of cardiovascular disease among groups with isolated versus concurrent hypertension and dyslipidemia.
		However, among patients with dyslipidemia and diabetes mellitus, the rates were not statistically significantly different (except for those younger than 45 years or 75 years or older with CAD), indicating that there may be no additional risk conferred by diabetes mellitus or that dyslipidemia and diabetes mellitus are collinear.
		This study estimated the prevalence of 3 chronic conditions (hypertension, dyslipidemia, and diabetes mellitus) with significant CV risk and found them to be common among patients in the VA. In fact, the VA population bears a larger burden of CV conditions than non-VA populations.
	www.ajmc.com /Article.cfm?Menu=1&ID=2781 (4213 words)

	NGC - NGC Summary
		Screening for dyslipidemia is warranted for all adults up to 75 years of age regardless of CAD risk status and for adults more than 75 years old who have multiple CAD risk factors.
		When dyslipidemia exists, secondary causes must be excluded, inasmuch as treatment of an underlying contributing disease may alleviate the lipid abnormality.
		Pharmacotherapy may consist of one, two, or, in cases of extreme dyslipidemia, three agents (that is, a statin, fibrate, and niacin).
	www.guideline.gov /summary/summary.aspx?ss=15&doc_id=2199&nbr=1425 (5700 words)

	Lipids Online Slides: insulin resistance, diabetic dyslipidemia
		Dyslipidemia in patients with the insulin resistance syndrome is characterized by an elevated level of total triglyceride, a reduced level of HDL cholesterol, and the presence of heterogeneity within LDL particles, with an increased proportion of LDL found as small, dense, cholesterol-poor particles.
		The data are more striking, however, for both HDL cholesterol, which was lower in the diabetics for both genders, and for triglycerides, which were higher in the diabetic subjects than in the normal control subjects.
		The pathophysiologic basis for diabetic dyslipidemia and its relation to insulin resistance is presented over the next four slides.
	www.lipidsonline.org /slides/slide01.cfm?tk=17&pg=2 (629 words)

	[Report] Drugs of Tomorrow 2001: Dyslipidemia - The Advent
		The dyslipidemia market is poised to enter a new era.
		Over the next 12 months, we will witness the launch of the 'superstatins', Crestor and pitavastatin, and between 2000 and 2007, the statin market is forecast to grow by 85% overall, to be worth almost $32bn in 2007.
		Dyslipidemia Pipeline Analysis Analyzes the dyslipidemia pipeline by class, number of indications, company type and by region.
	www.the-infoshop.com /study/dc7269_dyslipidemia.html (555 words)

	DYSLIPIDEMIA
		All of the dyslipidemias can be primary or secondary.
		In addition to weight reduction regimens, comorbid factors such as hypertension, dyslipidemia, and diabetes mellitus can be treated by usual medical methods.
		During such a treatment program, comorbidity factors such as hypertension, dyslipidemia, and diabetes mellitus can be treated by conventional medical therapy in the patient with clinically severe obesity.
	www.websters-online-dictionary.org /definition/english/Dy/Dyslipidemia.html (387 words)

	High Cholesterol and Dyslipidemia - New Treatments, October 2, 2005
		Dyslipidemias may be manifested by elevation of the serum total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides, and a decrease in the high-density lipoprotein (HDL) cholesterol.
		Elevated serum cholesterol levels are associated with the development of coronary heart disease, and aggressive cholesterol reduction results in increased rates of plaque regression.
		Secondary causes of dyslipidemia include hypothyroidism and a genetic predisposition, such as autosomal dominant familial hypercholesterolemia.
	www.ccspublishing.com /journals2a/dyslipidemia.htm (707 words)

	ADA: Dyslipidemia in Diabetics Needs More Aggressive Treatment (Site not responding. Last check: 2007-11-03)
		To compare attitudes and clinical practice patterns in the evaluation and treatment of dyslipidemia, Lawrence A. Leiter, MD, Professor, Department of Medicine and Nutritional Sciences, University of Toronto, Toronto, Canada, and colleagues surveyed 2,043 physicians from 50 countries worldwide specializing in the care of type 2 patients.
		Responses showed that physicians recognized that dyslipidemia is an important CVD risk factor among type 2 patients, and 91% of type 2 patients globally undergo CVD screening.
		The results thus identify a gap between screening for dyslipidemia and aggressive treatment of lipids in type 2 patients, which means that type 2 diabetics are not being managed optimally to thwart the risk of CVD and that type 2 diabetes is not widely considered as being a coronary risk equivalent, Dr. Leiter said.
	www.pslgroup.com /dg/24452a.htm (455 words)

	Management of Dyslipidemia in Primary Care - Introduction (Site not responding. Last check: 2007-11-03)
		Dyslipidemia is widely regarded as a major risk factor for coronary heart disease (CHD) and atherosclerotic cardiovascular disease (ASCVD) (NCEP II, 1993).
		This updated guideline for the Management of Dyslipidemia in Primary Care was started in mid-1999, at a meeting that also launched the development of a companion guideline, the Management of Ischemic Heart Disease (IHD) in Primary Care.
		The current guideline for the management of dyslipidemia represents hundreds of hours of diligent effort on the part of participants from the DoD, VHA, academia, and a team of private guideline facilitators.
	www.oqp.med.va.gov /cpg/DL/dl_cpg/content/intro.htm (1855 words)

	Diabetes In Control - Issue 170 Item 8 Treating Patients With Dyslipidemia Prior To Cardiovascular Dis (Site not responding. Last check: 2007-11-03)
		Treating dyslipidemia in patients with type 2 diabetes mellitus without cardiovascular disease appears to result in a clinical benefit equivalent to or greater than that seen with treating non-diabetic cardiovascular disease patients.
		Type 2 diabetes is linked to an increased risk of future cardiovascular events, and the risk of a cardiovascular event is as high among patients with diabetes as among non-diabetic patients who have had a cardiovascular event.
		According to the researchers, the analyses suggest "that dyslipidemia in patients with diabetes should be treated for primary prevention with the same intensity recommended for secondary prevention in patients with cardiovascular disease, before the development of cardiovascular disease," and this is consistent with the recent National Cholesterol Education Program guidelines.
	www.diabetesincontrol.com /modules.php?name=News&file=print&sid=1498 (407 words)

	Dyslipidemia: Type 2 diabetic patients can manage dyslipidemia with daily niacin treatment, October 2, 2002 (Site not responding. Last check: 2007-11-03)
		Investigators saw no evidence of liver toxicity or muscle disorders (Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
		"Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes," concluded Grundy and his coauthors.
		A search at www.NewsRx.net using the search term "dyslipidemia" yielded 20 articles in 6 specialized reports.
	www.obgyn.net /newsheadlines/headline_medical_news-Dyslipidemia-20021002-2.asp (423 words)

	Dyslipidemia of Central Obesity and Insulin Resistance
		DYSLIPIDEMIA OF CENTRAL OBESITY—; The hypertriglyceridemia associated with obesity and insulin resistance was thought to be secondary to the effects of elevated plasma insulin levels causing increased hepatic fatty acid esterification, which forms triglyceride (26).
		The association of small dense LDL with CAD (44,45) may be mediated by the small dense LDL, by the other dyslipidemia, or by the remaining components of the central obesity–insulin resistance syndrome.
		After therapy for hyperglycemia, much of the remaining dyslipidemia in type 2 diabetes is a reflection of the underlying central obesity and insulin resistance.
	journal.diabetes.org /diabetescare/FullText/Supplements/DiabetesCare/Supplement399/C10.htm (3266 words)

	Postgraduate Medicine: A new approach to atherogenic dyslipidemia
		In the article "Cholesterol Lowering in Diabetes," Dr Rosenson outlines what may be viewed as the state-of-the-art approach to dyslipidemia, which focuses on therapy with statins to decrease low-density lipoprotein cholesterol (LDL-C) levels.
		Once we understand the pathogenesis of atherogenic dyslipidemia, it becomes clear that the prevalence of low HDL-C levels, hypertriglyceridemia, and a predominance of small, dense LDL particles will increase in direct relation to the growing rate of obesity in the United States (see figure 3 in Dr. McGovern's article).
		Atherogenic dyslipidemia results in increased atherosclerotic plaque formation because of an imbalance between an increased number of small, dense LDL particles (which carry cholesterol to the vascular endothelium) and a decreased number of HDL particles (which remove cholesterol from atherosclerotic vessels).
	www.postgradmed.com /issues/2005/04_05/comm_reasner.htm (1612 words)

	Improvement of Dyslipidemia in Patients Switching from Stavudine to Tenofovir: Preliminary Results (Site not responding. Last check: 2007-11-03)
		The purpose of the current prospective, multicentre, switch study was to identify the most frequently occurring nucleoside reverse transcriptase inhibitor (NRTI)-associated toxicities that cause NRTI withdrawal in virologically suppressed HIV-infected patients.
		Unfortunately, HAART is increasingly associated with the emergence of morphological and metabolic disorders, mainly dyslipidemia, insulin resistance and fat redistribution syndromes, the so-called lipodystrophy syndrome.
		Most of these studies have substituted the PI with nevirapine (Viramune), efavirenz or abacavir (Ziagen), and have shown that dyslipidemia is at least partly reversible.
	www.hivandhepatitis.com /recent/metabolic/dyslipidemias/063004_a.html (973 words)

	Dyslipidemia in type 1 diabetes
		Dyslipidemia has been widely discussed in type 2 diabetes but very little information has been published in type 1.
		Since previous studies have primarily emphasized only the total cholesterol and total triglyceride concentrations with regard to dyslipidemia, this study aimed to assess the effects of improving glycemic control on the prevalence of dyslipidemia and on LDL and HDL cholesterol concentrations in type 1 diabetic patients compared with a non-diabetic control group.
		Based on the study results the authors suggest that intensive insulin therapy should be utilized as the initial treatment of choice for dyslipidemia in poorly controlled type 1 diabetes.
	www.medforum.nl /idm/dyslipidemiaintype1diabetes.htm (1181 words)

Try your search on: Qwika (all wikis)